For example, EV-associated mutations in oncogenic driver genes, such as EGFR and ALK, have been detected in EV samples from lung cancer patients, and their presence has been correlated with the tumor mutational status and treatment response [69,82,82,83,84,85]. This evidence concerns the gene EGFR and lung carcinoma.